AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of treating a subject suffering from Polycystic Ovary Syndrome (PCOS)

comprising:

identifying a subject suffering from PCOS; and

administering to said subject in need thereof an effective dose of a composition comprising at least one ~~purified~~ chromium-containing compound, wherein said chromium-containing compound is not chromium yeast.

2. (Currently amended) The method of Claim 1, wherein said ~~purified~~ chromium-containing compound is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, and chromium histidinate.

3. (Original) The method of claim 1, wherein said composition further comprises at least one chelating agent.

4. (Original) The method of claim 3, wherein said chelating agent is picolinic acid, nicotinic acid, or both.

5. (Currently amended) The method of claim 4, wherein said ~~purified~~ chromium-containing compound and said chelating agent are administered in a ratio of between about 1:10 and about 10:1 (w/w).

6. (Original) The method of claim 1, further comprising administering a cyclooxygenase inhibitor.

7. (Original) The method of claim 6, wherein said cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.

8. (Original) The method of claim 1, further comprising administering a mucolytic.

9. (Original) The method of claim 8, wherein said mucolytic is guaifenesin.

10. (Original) The method of claim 1, further comprising administering a salicin-containing herb.

11. (Original) The method of claim 10, wherein said salicin-containing herb is selected from the group consisting of *Boswellia serrata* (frankincense), *Betula lenta* (sweet birch), *Betula pubescens* (white birch), *Filipendula ulmaria* (meadowsweet), *Gautheria procumbens*

(wintergreens), *Polulus balsamifera*, *Populus jackii* (balm of Gilead) and *Salix alba* (white willow).

12. (Original) The method of claim 1, wherein said effective dose is between about 50 and about 10,000 micrograms.

13. (Original) The method of claim 1, wherein said composition is incorporated into a pharmaceutically acceptable carrier selected from the group consisting of a tablet, capsule, microbead, emulsion, powder, granule, suspension, syrup, and elixir.

14. (Original) The method of claim 1, wherein said composition is incorporated into a microbead.

15. (Previously amended) The method of claim 14, wherein said microbead is a sugar beadlet or microcrystalline cellulose beadlet and said purified chromium-containing compound is coated on said beadlet.

16. (Currently Amended) A method of treating Polycystic Ovary Syndrome (PCOS) comprising:

identifying a subject suffering from PCOS; and

administering to said subject an effective dose of a composition consisting essentially of at least one ~~purified~~ chromium-containing compound, wherein said compound is not chromium yeast.

17. (Currently Amended) The method of Claim 16, wherein said ~~purified~~ chromium-containing compound is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, and chromium histidinate.

18. (Previously added) The method of claim 16, wherein said composition further comprises at least one chelating agent.

19. (Previously added) The method of claim 18, wherein said chelating agent is picolinic acid, nicotinic acid, or both.

20. (Currently Amended) The method of claim 19, wherein said ~~purified~~ chromium-containing compound and said chelating agent are administered in a ratio of between about 1:10 and about 10:1 (w/w).

21. (Previously added) A method of treating Polycystic Ovary Syndrome (PCOS) comprising:

identifying a subject suffering from PCOS; and

administering to said subject an effective dose of a composition comprising at least one synthetic chromium complex.

22. (Previously added) The method of Claim 21, wherein said synthetic chromium complex is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, and chromium histidinate.

23. (Previously added) The method of claim 21, wherein said composition further comprises at least one chelating agent.

24. (Previously added) The method of claim 23, wherein said chelating agent is picolinic acid, nicotinic acid, or both.

25. (Previously added) The method of claim 24, wherein said synthetic chromium complex and said chelating agent are administered in a ratio of between about 1:10 and about 10:1 (w/w).